Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
ARTV Quote, Financials, Valuation and Earnings
Last price:
$3.69
Seasonality move
:
-1.06%
Day range:
$3.51 - $3.79
52-week range:
$1.47 - $13.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.79x
P/B ratio:
0.71x
Volume:
62K
Avg. volume:
246K
1-year change:
-70.32%
Market cap:
$92M
Revenue:
$251K
EPS (TTM):
-$3.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
-- | -$0.80 | -100% | -20.74% | $17.00 |
|
IRON
Disc Medicine, Inc.
|
-- | -$1.46 | -- | -72.53% | $118.17 |
|
KZR
Kezar Life Sciences, Inc.
|
-- | -$1.96 | -90.48% | -52.7% | $6.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.45 | -- | -21.07% | $36.50 |
|
OVID
Ovid Therapeutics, Inc.
|
$170.4K | -$0.15 | 2.96% | -25.17% | $4.19 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
$3.78 | $17.00 | $92M | -- | $0.00 | 0% | 46.79x |
|
IRON
Disc Medicine, Inc.
|
$93.79 | $118.17 | $3.5B | -- | $0.00 | 0% | -- |
|
KZR
Kezar Life Sciences, Inc.
|
$6.25 | $6.00 | $45.8M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
$27.64 | $36.50 | $1.9B | -- | $0.00 | 0% | -- |
|
OVID
Ovid Therapeutics, Inc.
|
$1.62 | $4.19 | $115.4M | -- | $0.00 | 0% | 17.42x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
8.3% | 1.916 | 16.72% | 11.06x |
|
IRON
Disc Medicine, Inc.
|
5.13% | 1.216 | 1.34% | 23.03x |
|
KZR
Kezar Life Sciences, Inc.
|
10.67% | 1.986 | 34.71% | 6.87x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
1.44% | 1.569 | 0.67% | 7.90x |
|
OVID
Ovid Therapeutics, Inc.
|
23.54% | 4.091 | 14.88% | 3.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
-$662K | -$22.9M | -43.85% | -47.44% | -5773.71% | -$19.8M |
|
IRON
Disc Medicine, Inc.
|
-$87K | -$67.7M | -31.4% | -32.82% | -- | -$47.8M |
|
KZR
Kezar Life Sciences, Inc.
|
-$227K | -$11.7M | -51.59% | -58.35% | -- | -$9.8M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$43K | -$45.9M | -45.23% | -45.61% | -- | -$34.5M |
|
OVID
Ovid Therapeutics, Inc.
|
$115K | -$12.5M | -48.14% | -59.7% | -9487.12% | -$12.9M |
Artiva Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns ARTV or IRON?
Disc Medicine, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Disc Medicine, Inc.'s return on equity of -32.82%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M IRONDisc Medicine, Inc.-- -$1.77 $604.4M -
What do Analysts Say About ARTV or IRON?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 350.33%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $118.17 which suggests that it could grow by 25.99%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Disc Medicine, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Disc Medicine, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 IRONDisc Medicine, Inc.12 0 0 -
Is ARTV or IRON More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.406%.
-
Which is a Better Dividend Stock ARTV or IRON?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or IRON?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Disc Medicine, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M IRONDisc Medicine, Inc.-- -- -- -$62.3M
-
Which has Higher Returns ARTV or KZR?
Kezar Life Sciences, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Kezar Life Sciences, Inc.'s return on equity of -58.35%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M KZRKezar Life Sciences, Inc.-- -$1.53 $92.9M -
What do Analysts Say About ARTV or KZR?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 350.33%. On the other hand Kezar Life Sciences, Inc. has an analysts' consensus of $6.00 which suggests that it could fall by -4%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Kezar Life Sciences, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Kezar Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 KZRKezar Life Sciences, Inc.0 4 0 -
Is ARTV or KZR More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kezar Life Sciences, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.462%.
-
Which is a Better Dividend Stock ARTV or KZR?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kezar Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Kezar Life Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or KZR?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Kezar Life Sciences, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Kezar Life Sciences, Inc.'s net income of -$11.2M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Kezar Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Kezar Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M KZRKezar Life Sciences, Inc.-- -- -- -$11.2M
-
Which has Higher Returns ARTV or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of -255.85%. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ARTV or NBY?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 350.33%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ARTV or NBY More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ARTV or NBY?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or NBY?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns ARTV or OLMA?
Olema Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M -
What do Analysts Say About ARTV or OLMA?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 350.33%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 32.06%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Olema Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 OLMAOlema Pharmaceuticals, Inc.8 0 0 -
Is ARTV or OLMA More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.
-
Which is a Better Dividend Stock ARTV or OLMA?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or OLMA?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M
-
Which has Higher Returns ARTV or OVID?
Ovid Therapeutics, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of -9210.61%. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M OVIDOvid Therapeutics, Inc.87.12% -$0.17 $58.5M -
What do Analysts Say About ARTV or OVID?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 350.33%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.19 which suggests that it could grow by 158.41%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Ovid Therapeutics, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Ovid Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 OVIDOvid Therapeutics, Inc.9 0 0 -
Is ARTV or OVID More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.
-
Which is a Better Dividend Stock ARTV or OVID?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or OVID?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 17.42x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M OVIDOvid Therapeutics, Inc.17.42x -- $132K -$12.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
